Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
*e-mail: [email protected] p p Structural model Exponential model Linear model Power model Interindividual variability - exponential model TVCL= CL; CL=TVCL*EXP( CL) TVV= V * WT; V=TVV*EXP( V) TVKA= Ka; KA=TVKA*EXP( Ka) Log-linear model Categorical covariate (0-present; 1-non present) Residual variability - proportional model C=CPRED*(1+ ) vs. J Clin Pharm Ther Eur J Clin Pharmacol P.5.d.003 No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis M. Jovanovic 1, K. Vucicevic1, B. Golubovic 1, S. Vezmar Kovacevic 1, M. Prostran 2, Z. Martinovic3, B. Miljkovic1 1Faculty of Pharmacya Department of Pharmacokinetics and Clinical Pharmacya Belgradea Serbia 2Faculty of Medicinea Department of Pharmacology Clinical Pharmacology and Toxicologya Belgradea Serbia 3Institute of Mental Healtha Department of Epilepsy and Clinical Neurophysiologya Belgradea Serbia Objectives: The aim of the study was to explore impact of carbamazepine aCBZ) daily dose on phenobarbital aPB) oral clearance aCL/F) in adult patients with epilepsy. The influence of CBZ is indefinite as previous results indicate variable effects on PB disposition. Decrease of PB CL/F in the presence of CBZ was recorded mostly in population of children [1,2]. Methods: A total of 205 measured PB concentrations wereused for analysis. Data were collected during routine therapeutic drug monitoring at the Unit for Antiepileptic Drugs at the Institute of Mental Health, Belgrade, Serbia. PB was administered either as monotherapy or in combination with other antiepileptic drugs. Patients a42±13 years) included in the study were at least three weeks on stable dosing regimens, for the assurance that the steady-state was reached for each of the antiepileptic drugs included in the therapy. Daily doses of PB were in the range from 25 to 300mg and dosage regimens were once, twice or three times a day. Eighty-one patients were co-treated with CBZ whose dose was in the range from 200 to 2000mg/day. Data analysis was performed by nonlinear mixed effects modelling approach using NONMEM ® software aversion 7.2, Icon Development Solutions, Ellicott City, MD, USA). The first-order conditional estimation method with interaction aFOCEI) was used for parameter estimation. Due to insufficient data in the absorption and distribution phase, only CL/F was estimated. Additive, proportional and exponential error model were tested for describing interindividual variability. For residual intraindividual variability of PB concentration additive, proportional and combination error models were evaluated. Results: An average daily dose of CBZ was 801.2±416.4mg. A one-compartment model with first-order absorption and elimination was used as a structural model. The interindividual variability was evaluated by an exponential model while residual variability was best described by proportional model. Objective function value aOFV) for base model was 966.7. Influence of CBZ daily dose was explored as categorical and continuous covariate. Covariate was tested against the base model and if OFV was significantly changed aat least 3.84, p<0.05) covariate was included in the model. Correlation between CBZ daily dose and PB CL/F was investigated using power, exponential, linear and log-linear model. However, there were not significant changes in OFV values, as well as in interindividual variability. The estimate of CL/F for a typical patient was in the range 0.261–0.321 l/h for the final model. Average CL/F of patients co-treated with CBZ was 0.320 l/h. Conclusion: In the present study inclusion of CBZ daily dose in the base model did not significantly improve data fitting. This confirms that CBZ does not contribute to interindividual variability of PB elimination. Therefore, in clinical practice adjustment of PB dose is not needed in the presence of CBZ. 1. Yukawa, E., 1999. Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients. J Clin Pharm Ther 24a2), 103–113. 2. Yukawa, E.L., To, H., Ohdo, S., Higuchi, S., Aoyama, T., 1998. Detection of a drug–drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. Eur J Clin Pharmacol 54a1), 69–74. Citation: Eur Neuropsychopharmacol. 2014;24aSuppl 2):S645 Keywords Pharmacokinetics Epilepsy Drug monitoring